Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
24 Apr 24
DEFA14A
Additional proxy soliciting materials
24 Apr 24
DEF 14A
Definitive proxy
24 Apr 24
8-K
Xencor Appoints Bart Cornelissen as Chief Financial Officer
9 Apr 24
8-K
Regulation FD Disclosure
6 Mar 24
10-K
2023 FY
Annual report
28 Feb 24
8-K
Xencor Reports Fourth Quarter and Full Year 2023 Financial Results
27 Feb 24
8-K
Entry into a Material Definitive Agreement
15 Nov 23
10-Q
2023 Q3
Quarterly report
7 Nov 23
8-K
Xencor Reports Third Quarter 2023 Financial Results
7 Nov 23
8-K
Entry into a Material Definitive Agreement
7 Nov 23
8-K
Xencor Announces Planned Retirement of Chief Financial Officer John Kuch
26 Oct 23
8-K
Xencor Appoints Barbara J. Klencke, M.D., to Board of Directors
19 Sep 23
10-Q
2023 Q2
Quarterly report
3 Aug 23
8-K
Xencor Reports Second Quarter 2023 Financial Results
3 Aug 23
8-K
Departure of Directors or Certain Officers
3 Jul 23
S-8
Registration of securities for employees
16 Jun 23
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Jun 23
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Jun 23
S-8 POS
Registration of securities for employees (post-effective amendment)
16 Jun 23
S-8 POS
Registration of securities for employees (post-effective amendment)
15 Jun 23
8-K
Submission of Matters to a Vote of Security Holders
14 Jun 23
10-Q
2023 Q1
Quarterly report
8 May 23
8-K
Xencor Reports First Quarter 2023 Financial Results
8 May 23
DEFR14A
Revised proxy
1 May 23
ARS
2022 FY
Annual report to shareholders
26 Apr 23
DEFA14A
Additional proxy soliciting materials
26 Apr 23
DEF 14A
Definitive proxy
26 Apr 23
8-K
Xencor Appoints Nancy Valente, M.D., as Chief Development Officer
26 Apr 23
8-K
Regulation FD Disclosure
10 Mar 23
8-K
Entry into a Material Definitive Agreement
28 Feb 23
S-3ASR
Automatic shelf registration
27 Feb 23
10-K
2022 FY
Annual report
24 Feb 23
8-K
Xencor Reports Fourth Quarter and Full Year 2022 Financial Results
23 Feb 23
10-Q
2022 Q3
Quarterly report
7 Nov 22
8-K
Xencor Reports Third Quarter 2022 Financial Results
7 Nov 22
8-K
Xencor Appoints Nancy Valente, M.D., to Board of Directors
9 Sep 22
S-8
Registration of securities for employees
3 Aug 22
10-Q
2022 Q2
Quarterly report
3 Aug 22
8-K
Xencor Reports Second Quarter 2022 Financial Results
3 Aug 22
Latest ownership filings
4
Nancy Valente
3 May 24
144
Notice of proposed sale of securities
2 May 24
4
Bart Jan Cornelissen
11 Apr 24
3
Bart Jan Cornelissen
11 Apr 24
4
John J Kuch
12 Mar 24
4
Celia Eckert
12 Mar 24
4
John R Desjarlais
12 Mar 24
4
Bassil I Dahiyat
12 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
144
Notice of proposed sale of securities
11 Mar 24
4
KURT A GUSTAFSON
7 Mar 24
4
Nancy Valente
7 Mar 24
4
John J Kuch
7 Mar 24
4
John R Desjarlais
7 Mar 24
4
Celia Eckert
7 Mar 24
4
Bassil I Dahiyat
7 Mar 24
144
Notice of proposed sale of securities
6 Mar 24
144
Notice of proposed sale of securities
5 Mar 24
144
Notice of proposed sale of securities
5 Mar 24
144
Notice of proposed sale of securities
5 Mar 24
144
Notice of proposed sale of securities
5 Mar 24
SC 13G/A
T. Rowe Price Investment Management, Inc.
16 Feb 24
4
John R Desjarlais
16 Feb 24
4
KEVIN CHARLES GORMAN
15 Feb 24
SC 13G/A
EcoR1 Capital, LLC
14 Feb 24
4
John R Desjarlais
14 Feb 24
SC 13G
T. Rowe Price Investment Management, Inc.
14 Feb 24
SC 13G/A
PRICE T ROWE ASSOCIATES INC /MD/
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
144
Notice of proposed sale of securities
13 Feb 24
SC 13G/A
PRIMECAP MANAGEMENT CO/CA/
12 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
SC 13G/A
STATE STREET CORP
25 Jan 24
SC 13G/A
BlackRock Inc.
19 Jan 24
4
Bassil I Dahiyat
29 Dec 23
144
Notice of proposed sale of securities
29 Dec 23
4
Barbara Klencke
19 Sep 23
3
Barbara Klencke
19 Sep 23